+1-800-267-5763
Geographic atrophy (GA) represents one of the most challenging forms of age-related macular degeneration (AMD) management, with significant implications for patient outcomes and quality of life. As the landscape of GA diagnosis and treatment continues to evolve, particularly with the emergence of complement inhibitor therapies, ophthalmologists require current, evidence-based knowledge to optimize patient care.
This module is designed specifically for busy clinicians who require essential GA information in a concise, accessible format. It distills key concepts from our comprehensive 4-module GA Essentials series, covering the most critical information that every clinician should know about GA.
What you’ll find in this module:
- Core pathophysiology and epidemiology concepts
- Essential diagnostic approaches and imaging techniques
- Current management strategies and emerging treatments
- Key clinical pearls for everyday practice
For comprehensive coverage: This summary provides the foundation for GA care, but clinical practice often requires deeper understanding. For detailed exploration of specific topics, please refer to the complete 4-module series.
Whether you’re refreshing your knowledge or seeking quick reference material, this module will equip you with the essential knowledge needed to provide optimal care for patients with GA.
Upon successful completion of this learning activity, the participant will be better able to:
- Explain the pathophysiology and key risk factors of geographic atrophy (GA).
- Identify the clinical signs and symptoms of GA and its impact on a patient’s quality of life.
- Differentiate between various imaging modalities used to diagnose GA.
- Describe current and emerging treatment options for GA, including lifestyle modifications, supplements, and novel therapies.
- Counsel patients on managing their condition and navigating vision loss due to GA.
Scientific Planning Committee and Conflicts of Interest Disclosure
| Dr. Bernard Hurley, MD, FRCSC | Chair of Scientific Planning Committee, Author I have a relationship with a for-profit and/or not-for-profit to disclose: Direct financial payments including receipt of honoraria: Allergan, Novartis, Alcon, Bayer, Roche, Biogen Membership on advisory boards or speakers’ bureaus: Teva, Apellis, Biogen, Roche, Bayer, Novartis |
| Dr. Jesia Hasan | Member of Scientific Planning Committee, Author I have a relationship with a for-profit and/or not-for-profit to disclose: Membership on advisory boards or speakers’ bureau: AbbVie, Astellas, Apotex, Apellis, Bayer, Biogen, Roche, Novartis |
| Dr. Amin Kherani, MD, FRCSC | Member of Scientific Planning Committee, Author I have a relationship with a for-profit and/or not-for-profit to disclose: Direct financial payments including receipt of honoraria: AbbVie, Alcon, Bayer, Bausch + Lomb, Novartis, Allergan, Roche and Appellis Funded grants or clinical trials: Bayer, Novartis, Roche/Genentech, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Ophthotech, Regeneron, Regenexbio, Iveris Bio Inc, Ophthea, Alexion All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity: MD Collaborate |
| Dr. Deepa Yoganathan | Member of Scientific Planning Committee, Author I have a relationship with a for-profit and/or not-for-profit to disclose: Direct financial payments including receipt of honoraria: Amgen, Astellas, Bayer, Biogen, Roche, Sentrex Membership on advisory boards or speakers’ bureau: Amgen, Astellas, Bayer, Biogen, Roche Funded grants or clinical trials: Roche, ANI |
Artificial Intelligence (AI) Disclosure
Artificial intelligence (AI) technology was utilized to generate some images contained within this educational module. These images are provided solely for illustrative and educational purposes. They do not depict actual patients or clinical findings and should not be interpreted as a substitute for clinical judgment or real-world diagnostic imaging.
Accreditation
This module is an Accredited Self-Assessment Activity (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Ophthalmological Society (COS). You may claim a maximum of 1.5 HOURS (credits are automatically calculated).
Acknowledgement of Support
This educational activity is supported by independent medical education grants from Apellis and Astellas.